Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by PitchinPennieson May 05, 2023 12:00pm
187 Views
Post# 35433143

Eternal Groundhog Day

Eternal Groundhog DayI like to look in on GUD every now and then, just to see if anything has changed. Nothing has changed. My personal view is that stasis will forever be the condition of this company. Ten or twenty years from now a few diehard investors will still be sitting on the edge of their seats in keen anticipation of Jonathan's next genius move, and everyone else will be watching the TV in the nursing home common room. I skipped Samira's schtick at last week's BB conference. A perky demeanor doesn't persuade me to park cash in a dubious asset. The market has moved on, and the money just isn't inclined to follow Jonathan's dream of selling out-licensed Rxs to men named Pedro.

That said, none of this is really worth the sniping that continues between the posters on this board, and, frankly, when you read through some of these heated comments you start to see signs of behavior on the autism spectrum. Sorry if that seems harsh, but that's my impression.


SS GUD right on track @ Bloom Burton conference

She spoke very confidently.
commented on the intrinsic value being well above where the sp is trading.
spoke very concisely,  and of the crowded room, just 2 questions.
Lots of enthusiasm!

<< Previous
Bullboard Posts
Next >>